Organization (Hospital)
Mayo Clinic
ClinicalTrials.gov lists Mayo Clinic as lead sponsor of 3,256 trials. It has 1,959 active development programs and 579 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 186 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 200 in 2026 and about 200 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (100 to 500), forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 15 trials are registered to start in 2027 or later.
Logo Mayo Clinic, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Mayo Clinic: 3,256 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (981)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Breast Neoplasms | 163 |
| Pain | 128 |
| Obesity | 119 |
| Diabetes Mellitus | 115 |
| Multiple Myeloma | 85 |
Showing 5 of 981 disease areas.
Trials by start year as sponsor or collaborator (37)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 15 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 186 |
| 2025 | 210 |
| 2024 | 204 |
| 2023 | 218 |
| 2022 | 199 |
| 2021 | 239 |
| 2020 | 207 |
| 2019 | 221 |
| 2018 | 201 |
| 2017 | 197 |
Showing 10 of 37 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 371 trials still running at the 2026-10-09 snapshot; registered median of 28 months across 2,332 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1,959)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Positron Emission Tomography (PET) | Prostatic Neoplasms | Phase 3 | 8 |
| DEXAMETHASONE | Multiple Myeloma | Phase 3 | 34 |
| Stereotactic Body Radiation Therapy | Prostatic Neoplasms | Phase 3 | 3 |
| CISPLATIN | Head and Neck Neoplasms | Phase 3 | 4 |
| Leukapheresis | Lymphoma, Non-Hodgkin | Phase 3 | 3 |
Showing 5 of 1,959 active programs.
Approved assets (579)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Positron Emission Tomography (PET) | 77 |
| DEXAMETHASONE | 47 |
| PEMBROLIZUMAB | 28 |
| Best Practice (which may include intravenous Alteplase) | 19 |
| +/- Bupivacaine HCl | 15 |
Showing 5 of 579 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 32% hit target (n=1360) | 35% on time (n=1310) |
Journals published in (1,135)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 71 |
| Circulation | 53 |
| Mayo Clinic proceedings | 50 |
| Gastroenterology | 45 |
| Gastrointestinal endoscopy | 45 |
Showing 5 of 1,135 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 4 | 0 | 2020-04-07 |
Financing and grant events (220)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-06-01 | NIH grant | 397,500 | Reporter |
| 2025-09-12 | NIH grant | 420,000 | Reporter |
| 2025-09-11 | NIH grant | 1,156,554 | Reporter |
| 2025-09-11 | NIH grant | 606,007 | Reporter |
| 2025-08-28 | NIH grant | 249,000 | Reporter |
Showing 5 of 220 events.
Organization relationships (427)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 240 |
| University of California System | Co sponsors trial with | 33 |
| Arizona's Public Universities | Co sponsors trial with | 18 |
| National Center for Research Resources (NCRR) | Co sponsors trial with | 14 |
| The Cleveland Clinic | Co sponsors trial with | 13 |
Showing 5 of 427 relationships.
Latest dated events (3,938)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2028-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-09-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 3,938 events.
CLIA clinical laboratory certificates (2)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| MAYO CLINIC | Certificate of compliance | Terminated |
| MAYO CLINIC | Certificate of compliance | Terminated |
Biomarker capability evidence (7,180)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| A1CF | Trial sponsor | Named in trial inclusion criteria |
| AAAS | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| AARS1 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| AARS2 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| ABAT | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
Showing 5 of 7,180 evidence rows.
Biomarkers this organization publishes on (3,946)
Shown in this order: most publications first.
Showing 5 of 3,946 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.